Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Forest Laboratories and AstraZeneca to Co-Develop and Commercialize a Late Stage Next Generation Anti-Infective

Published: Thursday, August 13, 2009
Last Updated: Thursday, August 13, 2009
Bookmark and Share
The definitive collaboration agreement will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan.

Forest Laboratories and AstraZeneca announced they have entered into a definitive collaboration agreement to co-develop and commercialize ceftaroline in all markets outside the United States, Canada and Japan.

Ceftaroline is Forest’s late stage, next generation cephalosporin being investigated for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). Ceftaroline demonstrates bactericidal activity against a broad range of pathogens commonly implicated in cSSSI and CABP, including methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumoniae (MDRSP).

Under the terms of the agreement AstraZeneca will pay Forest an undisclosed signing fee, sales-related royalties and payments for reaching certain sales milestones. AstraZeneca will assume responsibility for the development, regulatory approval and commercialization of ceftaroline in the licensed territory. The parties will collaborate on future development activities. Further financial terms were not disclosed.

Forest expects to file a New Drug Application in the U.S. by the end of 2009 with AstraZeneca filing a Marketing Authorization Application in Europe by the end of 2010.

The strong demand for new anti-infectives is being driven by the ever-increasing development of bacterial resistance to marketed antibiotics. Currently, many bacterial infections have few satisfactory treatment options and rates of pneumonia and skin infections being caused by MRSA are increasing.

Forest has conducted four pivotal, Phase III trials with ceftaroline to assess its efficacy and safety profile in treating cSSSI and CABP. The trials showed that versus currently marketed comparators, ceftaroline exhibited activity against gram-positive pathogens (including MRSA and MDRSP) and common gram-negative pathogens and was generally well tolerated. If approved, ceftaroline could be used as a first-line treatment for both CABP and cSSSI.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca to Invest in New Biologics Manufacturing Facility
New facility in Södertälje, Sweden, to support accelerating biologics portfolio.
Thursday, May 21, 2015
AstraZeneca and Montreal Heart Institute Partner
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits.
Thursday, May 14, 2015
AstraZeneca and Abbott Partner
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma.
Thursday, May 14, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Forms CRISPR Collaborations
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.
Thursday, January 29, 2015
AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
AstraZeneca Buys Rights to Almirall Respiratory Franchise
AstraZeneca agrees an initial consideration of $875 million on completion, which may rise to $1.22 billion in development, launch, and sales-related milestones.
Monday, August 04, 2014
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca system implemented with input from Tessella wins 2014 Bio-IT World Best Practices Award
Award winning Clinical & Health IT system allows AstraZeneca to respond rapidly to safety concerns and swiftly identify risk factors for adverse events, protecting trial participants while rescuing trials from costly late-stage failure.
Saturday, May 10, 2014
AstraZeneca Board Rejects Pfizer Proposal
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.
Friday, May 02, 2014
AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance Assets
Global agreement strengthens AstraZeneca’s commitment to diabetes.
Monday, December 23, 2013
AstraZeneca to Invest £120 Million in New Manufacturing Facility
AstraZeneca invests to continue production of Zoladex, an injectable treatment for patients with prostate cancer.
Tuesday, November 12, 2013
AstraZeneca to Acquire Pearl Therapeutics to Strengthen Respiratory Portfolio
Pearl Therapeutics is focused on the development of inhaled small-molecule therapeutics for respiratory disease.
Wednesday, June 12, 2013
AstraZeneca to Acquire Omthera Pharmaceuticals
Acquisition includes the take-over of NDA-ready novel dyslipidemia treatment to complement cardiovascular portfolio.
Wednesday, May 29, 2013
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Paving the way to Better Ovarian Cancer Diagnosis
Aïcha BenTaieb will present her invention for automated identification of ovarian cancer’s many subtypes at an international conference this fall.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!